PressMay 13, 2022 Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home
PressMay 12, 2022 Osmind Raises $40M Series B Round Led by DFJ Growth to Expand Platform for Breakthrough Mental Health Research and Treatment
PressMay 11, 2022 MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
PressMay 10, 2022 Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
PressMay 5, 2022 PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
PressMay 4, 2022 Nova Mentis Psilocybin Manufacturer Receives Approved Health Canada Importation Permit
PressMay 3, 2022 COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
PressMay 2, 2022 Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
PressApril 29, 2022 Allied Corp Announces Purchase Order Continuing into Monthly Supply Agreement for Brazilian Specialty Cancer Care Hospital
PressApril 26, 2022 Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
PressApril 25, 2022 Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its DMT and 5-MeO-DMT Drug Candidate Compounds
PressApril 22, 2022 Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
